No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
339 |
4. Check minimum number of eventsNone |
339 |
5. Include endpointsNone |
339 |
6. Filter based on genotype QC (FinnGen only) |
323 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Chronic myeloid leukaemia, including Hilmo
based on the number of shared cases.
Similar with more cases:
- Primary_lymphoid and hematopoietic malignant neoplasms
- Liquid cancers, helper endpoint
- Malignant neoplasm
- Malignant neoplasm, wide definition for exclusion
- Neoplasms
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 323 | 147 | 176 |
| Unadjusted period prevalence (%) | 0.07 | 0.05 | 0.08 |
| Median age at first event (years) | 60.75 | 57.61 | 63.37 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 339
- Matched controls
- 3390
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
XW000
NOMESCO Finland
Bone marrow biopsy
101.8
307.7
186
40
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
1144.4
307.7
299
22
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
307.7
334
*
189
Kela drug reimbursment
Imatinib
+∞
219.4
186
*
L01XE01
ATC
[U] imatinib
+∞
178.4
155
*
L01XX05
ATC
hydroxycarbamide; oral
71.1
174.3
97
19
9863/3-C42.1
ICD-O-3
Chronic myeloid leukemia, NOS, of bone marrow
+∞
156.8
138
*
M04AA01
ATC
allopurinol; systemic
16.0
152.7
189
247
L01EA01
ATC
imatinib; oral
+∞
134.6
120
*
316
Kela drug reimbursment
Imatinib
+∞
111.8
101
*
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
+∞
78.2
72
*
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
169.4
66.7
68
5
212
Kela drug reimbursment
Gout
24.1
64.9
48
23
152
Kela drug reimbursment
Nilotinib
+∞
64.7
60
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.6
61.0
108
197
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
+∞
51.4
48
*
L03AA02
ATC
filgrastim; parenteral
567.2
50.8
49
*
WW500
NOMESCO Finland
Blood transfusion
18.3
50.4
42
26
L01XX28
ATC
[U] imatinib
+∞
50.3
47
*
150
Kela drug reimbursment
Dasatinib
+∞
48.1
45
*
A04AA01
ATC
ondansetron; systemic, rectal
16.4
47.6
42
29
L01XE06
ATC
[U] dasatinib
+∞
41.5
39
*
328
Kela drug reimbursment
Nilotinib
+∞
41.5
39
*
L01XE08
ATC
[U] nilotinib
+∞
41.5
39
*
127
Kela drug reimbursment
Transplant complication
58.8
39.7
46
9
L01EA03
ATC
nilotinib; oral
+∞
38.3
36
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
8.4
37.6
53
73
R50.9
ICD-10 Finland
Fever, unspecified
4.9
34.0
93
244
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
10.1
28.7
34
37
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
28.5
27
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.9
27.0
69
169
324
Kela drug reimbursment
Dasatinib
+∞
26.4
25
*
WW200
NOMESCO Finland
Immunization
11.2
25.7
28
27
A03FA01
ATC
metoclopramide; systemic, rectal
4.2
25.5
80
230
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
24.3
23
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.5
22.8
48
99
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.1
22.5
200
1084
JN4AD
NOMESCO Finland
Body CT examination
5.9
22.5
43
81
Z51.5
ICD-10 Finland
Palliative care
8.2
22.5
31
41
9875/3-C42.1
ICD-O-3
Chronic myelogenous leukemia, BCR/ABL positive of bone marrow
+∞
22.1
21
*
L04AA01
ATC
[U] ciclosporin
40.0
21.1
26
7
L01EA02
ATC
dasatinib; oral
+∞
21.1
20
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
17.3
21.1
33
21
JN4BD
NOMESCO Finland
Extensive body CT
6.3
20.7
37
65
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
+∞
20.0
19
*
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
+∞
20.0
19
*
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
111.6
19.8
21
*
N02AA05
ATC
oxycodone; systemic
3.6
19.5
76
251
C92.9
ICD-10 Finland
Myeloid leukaemia, unspecified
+∞
18.9
18
*
170
Kela drug reimbursment
Bosutinib
+∞
18.9
18
*
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
+∞
18.9
18
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
106.0
18.8
20
*
D72.9
ICD-10 Finland
Disorder of white blood cells, unspecified
46.8
18.5
22
5
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.8
18.2
35
66
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
55.7
18.2
21
*
A05AA02
ATC
ursodeoxycholic acid; oral
15.7
18.0
29
20
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
17.9
17
*
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
189.5
17.7
18
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
30.7
17.7
23
8
130
Kela drug reimbursment
Malignant tumour
+∞
16.8
16
*
L03AB05
ATC
interferon alfa-2b; parenteral
+∞
16.8
16
*
C95.9
ICD-10 Finland
Leukaemia, unspecified
+∞
16.8
16
*
H02AB02
ATC
dexamethasone; systemic
17.9
16.3
25
15
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
6.6
15.7
26
42
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
4.8
15.6
37
84
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
167.4
15.6
16
*
121
Kela drug reimbursment
Severe hypofunction of sexual glands
13.3
15.1
26
21
C03CA01
ATC
furosemide; systemic
2.6
15.1
134
689
B03XA02
ATC
darbepoetin alfa; parenteral
16.0
15.1
24
16
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.9
14.9
47
133
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
26.4
14.9
20
8
9823/3-C42.1
ICD-O-3
B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma of bone marrow
+∞
14.7
14
*
360
Kela drug reimbursment
Bosutinib
+∞
14.7
14
*
PJA12
NOMESCO Finland
Sentinel node biopsy
156.5
14.6
15
*
B03XA01
ATC
erythropoietin; parenteral
55.8
13.9
16
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
78.4
13.7
15
*
116
Kela drug reimbursment
Prostate cancer
+∞
13.6
13
*
115
Kela drug reimbursment
Breast cancer
+∞
13.6
13
*
B73
ICPC
Leukaemia
+∞
13.6
13
*
ZX120
NOMESCO Finland
Intravenous
4.2
13.5
38
99
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.4
13.3
54
181
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
41.9
13.3
16
*
J05AB11
ATC
valaciclovir; oral
2.9
13.1
70
276
WZC00
NOMESCO Finland
Treatment plan or consultation
2.5
12.9
111
556
J01MA14
ATC
moxifloxacin; systemic
3.5
12.8
48
153
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
72.7
12.7
14
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
72.7
12.7
14
*
C82.1
ICD-10 Finland
Follicular lymphoma grade II
+∞
12.6
12
*
L01EA04
ATC
bosutinib; oral
+∞
12.6
12
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
12.6
12
*
XX3DW
NOMESCO Finland
Time consuming IT work
4.7
12.2
29
66
L04AD01
ATC
ciclosporin; systemic
17.2
11.8
18
11
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.7
11.7
77
337
L03AA04, ,
ATC
+∞
11.5
11
*
WW302
NOMESCO Finland
Allogenic transfer of stem cells from relative
+∞
11.5
11
*
C90.0
ICD-10 Finland
Multiple myeloma
124.1
11.5
12
*
A04AA02
ATC
granisetron; systemic, transdermal
124.1
11.5
12
*
D64.9
ICD-10 Finland
Anaemia, unspecified
3.1
11.3
51
182
J01MA12
ATC
levofloxacin; systemic
2.6
11.0
76
340
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
44.9
11.0
13
*
Y84.8
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
44.9
11.0
13
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
10.5
10
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
10.5
10
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
10.5
10
*
L01XE14
ATC
[U] bosutinib
+∞
10.5
10
*
2051A
ICD-9 Finland
Myeloid leukaemia, Chronic
+∞
10.5
10
*
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
+∞
10.5
10
*
Y84
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
16.7
10.5
16
10
WF002
NOMESCO Finland
Radical radiotherapy
33.7
10.4
13
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.5
10.3
26
62
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.4
9.9
37
117
J02AC03
ATC
voriconazole; systemic
56.7
9.7
11
*
L02AE02
ATC
leuprorelin; implant, parenteral
31.0
9.5
12
*
R72
ICD-10 Finland
Abnormality of white blood cells, not elsewhere classified
31.0
9.5
12
*
A07AA02
ATC
nystatin; oral
3.8
9.5
30
85
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
22.4
9.4
13
6
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
9.4
9
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
9.4
9
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
9.4
9
*
C91.9
ICD-10 Finland
Lymphoid leukaemia, unspecified
+∞
9.4
9
*
A01AB04
ATC
amphotericin B; local oral
3.7
9.3
30
86
B01AB10
ATC
tinzaparin; parenteral
3.3
9.1
36
118
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
9.9
8.9
17
18
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.1
8.8
116
677
D47.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue, unspecified
51.3
8.7
10
*
J05AB01
ATC
aciclovir; systemic
2.2
8.6
83
429
NK6AN
NOMESCO Finland
Total body bone isotope imaging
92.3
8.5
9
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
8.4
8
*
373
Kela drug reimbursment
Ponatinib
+∞
8.4
8
*
C93.1
ICD-10 Finland
Chronic myelomonocytic leukaemia
+∞
8.4
8
*
C44.32
ICD-10 Finland
Spinocellular carcinoma of the skin on another or unspecified part of the face
+∞
8.4
8
*
L02BB03
ATC
bicalutamide; oral
+∞
8.4
8
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.1
8.3
99
555
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
4.0
8.2
24
64
TPX10
NOMESCO Finland
Implantation of vascular injection port
8.5
8.2
17
21
A41.9
ICD-10 Finland
Sepsis, unspecified
4.3
8.1
21
51
UJF32
NOMESCO Finland
Coloscopy
2.1
8.0
94
523
306
Kela drug reimbursment
Erythropoietin and darbepoetin
46.1
7.7
9
*
L03AA13
ATC
pegfilgrastim; parenteral
46.1
7.7
9
*
H02AB04
ATC
methylprednisolone; systemic
2.4
7.7
60
282
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
4.0
7.7
22
58
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.2
7.6
31
104
L02BA01
ATC
tamoxifen; oral
81.8
7.4
8
*
L02BG04
ATC
letrozole; oral
13.8
7.4
12
9
ZX112
NOMESCO Finland
Subcutaneous
13.8
7.4
12
9
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
6.5
7.3
18
29
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
7.3
7
*
9945/3-C42.1
ICD-O-3
Chronic myelomonocytic leukemia, NOS, of bone marrow
+∞
7.3
7
*
WW409
NOMESCO Finland
Other aferesis
+∞
7.3
7
*
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
+∞
7.3
7
*
1529, ,
Kela drug reimbursment
+∞
7.3
7
*
JN3AD
NOMESCO Finland
Abdominal CT examination
2.6
7.2
42
172
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
5.7
7.0
19
35
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.9
6.8
105
640
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
7.4
6.8
15
21
H02AB09
ATC
hydrocortisone; systemic
7.1
6.6
15
22
ZXD05
NOMESCO Finland
Urgent procedure
1.9
6.5
104
639
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
71.1
6.4
7
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.0
6.4
75
414
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
3.6
6.4
21
61
L01BB02
ATC
mercaptopurine; oral
11.3
6.3
11
10
A41.1
ICD-10 Finland
Sepsis due to other specified staphylococcus
18.4
6.3
9
5
C92.2
ICD-10 Finland
Atypical chronic myeloid leukaemia, BCR/ABL- negative
+∞
6.3
6
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
6.3
6
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
6.3
6
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
JFB31
NOMESCO Finland
Laparoscopic right hemicolectomy
+∞
6.3
6
*
C92.7
ICD-10 Finland
Other myeloid leukaemia
+∞
6.3
6
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
6.3
6
*
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
+∞
6.3
6
*
C95.1
ICD-10 Finland
Chronic leukaemia of unspecified cell type
+∞
6.3
6
*
9960/3-C42.1
ICD-O-3
Myeloproliferative neoplasm, NOS, of bone marrow
27.2
6.3
8
*
D70.89
ICD-10 Finland
Neutropenic splenomegaly
27.2
6.3
8
*
H02AB06
ATC
prednisolone; systemic
1.8
6.0
162
1161
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
106
29
52.73
177.06
2.4
1.5
—
—
—
0
0
154
223
11.82
111.67
4.5
2.1
70.34
66.19
e9/l
0.58
119
175
172
311
10.20
103.17
5.2
2.0
1.83
1.70
%
0.89
166
279
93
0
+∞
102.41
15.2
0.0
—
—
—
0
0
89
0
+∞
97.75
11.5
0.0
—
—
—
0
0
197
709
5.25
51.19
6.5
2.3
339.43
8298.54
umol/l
3.57
190
625
267
1256
6.30
49.09
17.0
3.7
11.43
11.70
umol/l
0.12
262
1177
283
1407
7.12
48.48
28.1
6.1
3.85
4.27
e9/l
0.88
270
1247
63
103
7.28
38.45
1.8
1.8
1.24
1.51
g/l
1.26
56
91
247
1233
4.70
38.11
14.7
5.4
1.21
1.21
mmol/l
0.57
218
1073
45
52
9.83
36.62
1.6
2.0
—
—
—
0
0
35
29
13.34
35.56
2.3
1.5
—
—
—
0
0
35
29
13.34
35.56
2.3
1.5
—
—
—
0
0
32
25
14.03
33.61
2.2
1.2
33.47
33.28
pg
0.06
32
25
37
37
11.10
33.30
2.7
1.5
—
—
—
0
0
38
40
10.57
33.00
1.1
1.2
137.60
113.14
u/ml
—
10
7
223
1111
3.94
32.61
13.3
4.7
1.21
1.21
mmol/l
0.31
215
996
37
41
10.01
30.93
2.5
1.5
—
—
—
0
0
97
320
3.85
25.48
3.2
2.3
22.56
22.83
%
0.07
84
276
27
28
10.39
23.52
2.7
1.5
—
—
—
0
0
31
41
8.22
22.45
6.6
3.7
53.19
58.20
%
1.06
31
41
243
1552
3.00
18.82
8.1
4.0
6.74
6.73
mmol/l
0.01
235
1444
28
41
7.35
18.54
6.5
3.3
3.04
4.46
e9/l
2.77
28
41
97
387
3.11
18.25
2.8
1.8
—
—
—
0
0
156
832
2.62
16.64
3.3
2.3
57.85
62.56
u/l
0.36
151
769
21
7
31.84
16.31
5.9
1.9
—
—
—
0
0
129
636
2.66
16.04
2.8
2.1
2.79
3.01
mg/l
0.52
119
539
24
35
7.30
15.91
1.8
1.3
—
—
—
0
0
162
897
2.54
15.76
4.2
3.0
—
—
—
0
0
28
50
6.01
15.35
1.1
1.1
—
—
—
0
0
25
18
14.89
15.27
1.6
1.6
—
—
—
0
0
25
18
14.89
15.27
1.6
1.6
—
—
—
0
0
186
1110
2.50
15.25
5.4
2.2
—
—
—
0
0
71
267
3.10
14.52
2.5
1.8
—
—
—
0
0
72
273
3.08
14.52
2.4
1.8
—
—
—
0
0
179
1074
2.41
14.17
4.2
2.6
261.27
128.83
ug/l
3.49
173
985
51
159
3.60
14.07
2.0
1.5
—
—
—
0
0
20
12
17.61
13.15
4.1
2.0
559.95
678.50
e6/l
0.42
20
12
34
83
4.44
13.10
2.6
1.7
1.81
2.08
ug/l
0.07
34
74
25
47
5.66
12.97
1.1
1.2
352.11
241.68
u/ml
0.86
19
28
193
1236
2.30
12.65
12.6
15.4
1.19
1.32
inr
1.23
56
344
29
67
4.64
11.94
1.8
1.2
—
—
—
0
0
32
81
4.26
11.76
2.3
3.6
—
—
—
0
0
21
38
5.83
11.31
1.0
1.0
—
—
—
0
0
21
23
9.65
10.67
1.6
1.5
—
—
—
0
0
143
864
2.13
10.20
6.4
2.8
40.46
32.99
u/l
0.59
137
819
26
64
4.32
9.89
1.4
1.3
—
—
—
0
0
19
22
9.08
9.42
2.9
1.5
—
—
—
0
0
9
0
+∞
9.41
1.0
0.0
—
—
—
0
0
20
27
7.80
9.07
1.9
1.4
—
—
—
0
0
101
555
2.17
9.01
5.8
1.9
—
—
—
0
0
17
19
9.36
8.64
3.1
1.1
—
—
—
0
0
17
19
9.36
8.64
3.1
1.1
—
—
—
0
0
17
19
9.36
8.64
3.1
1.1
—
—
—
0
0
19
26
7.67
8.57
2.9
1.4
—
—
—
0
0
100
559
2.12
8.47
1.9
1.6
1.56
1.01
mg/l
1.22
82
423
61
287
2.37
7.80
9.6
5.9
12.16
11.55
kpa
0.45
56
277
121
748
1.96
7.65
4.6
3.0
665.88
149.37
e6/l
0.37
104
565
14
14
10.37
7.60
1.0
1.1
—
—
—
0
0
17
24
7.40
7.57
1.9
1.5
—
—
—
0
0
60
288
2.32
7.31
9.7
6.0
1.11
1.43
mmol/l
0.20
44
228
14
18
8.06
6.68
1.9
1.8
—
—
—
0
0
19
50
3.97
6.63
1.9
1.4
—
—
—
0
0
16
26
6.40
6.55
1.9
1.3
—
—
—
0
0
21
60
3.67
6.55
1.4
1.3
—
1.06
—
0
6
14
19
7.63
6.48
3.1
1.8
—
—
—
0
0
10
7
14.67
6.43
1.8
3.4
—
—
—
0
0
11
10
11.32
6.34
1.6
2.0
—
—
—
0
0
11
10
11.32
6.34
1.6
2.0
—
—
—
0
0
37
152
2.61
6.28
1.9
1.7
—
—
—
0
0
90
537
1.92
6.13
1.8
1.8
1263.66
1149.68
nmol/l
0.54
83
404
106
675
1.83
5.86
1.9
1.5
20.31
21.06
nmol/l
0.19
96
576
107
690
1.80
5.65
4.4
2.8
0.66
0.40
e6/l
0.46
93
504
9
7
13.16
5.61
4.4
1.0
—
—
—
0
0
9
7
13.16
5.61
4.3
1.0
—
—
—
0
0
9
7
13.16
5.61
4.4
1.0
—
—
—
0
0
12
18
6.87
5.30
1.8
1.2
20620.50
25541.18
e6/l
—
6
11
14
26
5.57
5.28
1.5
1.6
—
—
—
0
0
13
22
6.10
5.27
1.0
1.0
—
—
—
0
0
5
0
+∞
5.22
1.4
0.0
—
—
—
0
0
10
12
8.55
5.09
4.2
1.2
—
—
—
0
0
10
12
8.55
5.09
4.2
1.2
—
—
—
0
0
9
9
10.23
5.05
1.9
1.1
—
—
—
0
0
9
9
10.23
5.05
1.9
1.1
—
—
—
0
0
35
156
2.39
5.02
1.7
1.5
—
—
—
0
0
38
179
2.26
4.82
4.3
3.6
0.46
1.87
mmol/l
1.12
26
131
26
103
2.65
4.75
1.5
1.3
—
—
—
0
0
13
26
5.16
4.68
1.8
1.2
—
—
—
0
0
7
5
14.25
4.59
7.6
1.0
—
—
—
0
0
8
8
10.20
4.54
2.0
1.1
—
—
—
0
0
8
8
10.20
4.54
2.0
1.1
—
—
—
0
0
19
66
2.99
4.41
1.6
1.3
226.50
320.88
ug/g
1.04
12
39
155
1169
1.60
4.32
2.3
2.0
91.96
95.25
pmol/l
0.38
108
584
75
468
1.77
4.31
4.1
2.0
2.45
2.44
mmol/l
0.13
75
398
7
6
11.87
4.29
1.0
1.0
—
—
—
0
0
65
389
1.83
4.28
4.5
2.9
2.32
2.58
e6/l
0.11
41
201
240
2016
1.65
4.22
6.0
4.0
13.82
11.28
mm/h
1.93
232
1847
145
1081
1.60
4.21
3.8
3.6
24.23
74.15
ng/l
0.93
119
771
16
53
3.12
4.02
1.8
2.0
129.40
133.55
g/l
—
10
38
17
60
2.93
3.85
2.3
1.3
—
—
—
0
0
44
253
1.85
3.29
5.5
3.0
2.43
2.21
mmol/l
0.11
36
207
22
98
2.33
3.20
4.0
1.6
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
69
2.54
3.01
2.9
2.2
0.34
0.36
u/ml
0.09
12
34
160
1285
1.46
3.00
3.8
3.6
0.00
0.00
estimate
-0.00
28
208
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
5
10.12
2.99
1.2
4.2
109.00
139.00
%
—
5
5
7
13
5.47
2.88
1.4
1.0
—
—
—
0
0
157
1272
1.44
2.74
5.0
5.0
0.00
0.00
estimate
-0.00
33
212
12
40
3.07
2.72
1.5
2.4
59331.60
6786.33
u/l
—
5
15
6
10
6.08
2.71
1.0
1.1
—
—
—
0
0
63
425
1.59
2.66
3.7
2.6
1.48
1.20
e6/l
0.28
41
236
11
36
3.12
2.59
1.1
1.4
—
—
—
0
0
12
42
2.92
2.57
1.3
1.5
—
—
—
0
0
12
42
2.92
2.57
1.3
1.5
—
—
—
0
0
5
7
7.23
2.55
1.8
1.1
1.32
4.90
nmol/l
—
5
7
20
95
2.17
2.54
2.3
1.5
—
—
—
0
0
24
123
2.02
2.52
5.4
4.2
24.43
25.01
mmol/l
0.36
24
117
14
57
2.52
2.48
2.1
1.2
—
—
—
0
0
10
32
3.19
2.45
2.3
1.1
—
—
—
0
0
10
33
3.09
2.37
2.3
1.1
—
—
—
0
0
10
33
3.09
2.37
2.3
1.1
—
—
—
0
0
10
33
3.09
2.37
2.3
1.1
—
—
—
0
0
10
33
3.09
2.37
2.3
1.1
—
—
—
0
0
10
33
3.09
2.37
2.3
1.1
—
—
—
0
0
292
2695
1.60
2.36
35.9
11.9
20.41
23.04
mg/l
0.69
266
2053
34
201
1.77
2.35
3.9
2.0
57.24
65.13
ml/min/173m2
0.84
21
78
154
1268
1.39
2.35
3.8
3.6
0.00
0.00
estimate
0.50
32
230
11
40
2.81
2.29
1.2
1.7
—
—
—
0
0
11
40
2.81
2.29
1.2
1.1
—
—
—
0
0
8
23
3.54
2.28
1.1
1.6
—
—
—
0
0
6
14
4.34
2.16
1.0
1.4
14.53
12.63
ug/l
—
6
14
9
31
2.95
2.08
1.0
1.8
—
—
—
0
0
6
15
4.05
2.04
1.7
2.6
991.67
605.00
u/ml
—
6
15
182
1564
1.35
2.03
2.7
2.8
—
—
—
0
0
20
106
1.94
1.95
1.4
1.8
—
151.43
—
0
7
5
11
4.60
1.95
1.0
1.5
—
—
—
0
0
5
11
4.60
1.95
17.4
1.4
189.60
215.45
u/l
—
5
11
90
697
1.40
1.91
4.1
3.6
0.00
0.01
estimate
0.50
28
211
36
231
1.62
1.88
3.9
2.7
—
—
—
0
0
72
538
1.43
1.87
5.8
3.8
126.89
371.83
ng/l
1.33
62
428
6
17
3.57
1.84
1.7
1.1
—
—
—
0
0
15
73
2.10
1.83
1.3
1.5
—
—
—
0
0
225
2019
1.34
1.77
4.0
3.7
15.18
14.85
pmol/l
1.09
217
1813
5
13
3.89
1.72
3.4
1.4
—
—
—
0
0
5
15
3.37
1.53
1.4
1.3
—
—
—
0
0
6
21
2.89
1.51
1.0
1.1
—
—
—
0
0
249
2304
1.30
1.35
46.2
13.9
14.99
14.91
%
0.14
249
2269
119
1016
1.26
1.24
4.0
3.6
—
—
—
0
0
6
26
2.33
1.19
1.2
1.1
—
—
—
0
0
21
138
1.56
1.05
2.6
2.1
0.65
0.68
%
0.22
21
138
75
618
1.27
1.04
4.1
3.8
1.01
1.02
kg/l
2.44
14
92
69
564
1.28
1.02
1.5
1.8
541.82
432.50
pmol/l
0.98
55
457
6
27
2.24
0.94
1.0
1.1
—
—
—
0
0
6
29
2.09
0.89
2.0
2.2
—
—
—
0
0
8
43
1.88
0.88
2.4
2.3
106.00
104.81
mmol/l
—
8
43
6
33
1.83
0.79
1.7
1.3
—
—
—
0
0
0
27
0.00
0.78
0.0
1.2
—
—
—
0
0
14
91
1.56
0.76
2.1
1.6
—
—
—
0
0
19
133
1.45
0.75
1.2
1.3
—
—
—
0
0
11
70
1.59
0.66
2.8
1.7
174.91
252.02
pmol/l
1.86
11
65
5
29
1.73
0.64
2.8
4.4
—
—
—
0
0
5
29
1.73
0.64
1.0
1.1
—
—
—
0
0
266
2560
1.18
0.60
31.0
10.7
74.13
80.04
ml/min/173m2
3.80
243
2063
13
89
1.48
0.59
1.2
1.2
—
—
—
0
0
13
89
1.48
0.59
1.2
1.2
—
—
—
0
0
0
23
0.00
0.58
0.0
1.7
—
—
—
0
0
8
54
1.49
0.57
1.4
1.4
—
—
—
0
0
6
36
1.68
0.57
1.3
1.4
68.52
63.97
pmol/l
—
6
36
192
1810
1.14
0.56
3.4
3.1
63.46
47.94
u/l
1.05
181
1692
8
124
0.64
0.55
1.0
1.0
—
—
—
0
0
18
237
0.75
0.54
1.7
1.8
—
—
—
0
0
256
2473
1.14
0.47
5.2
4.5
1.89
2.42
mu/l
0.54
247
2242
42
362
1.18
0.42
11.0
6.4
—
—
—
0
0
298
3037
0.84
0.41
53.6
17.6
4.06
4.55
e12/l
29.68
292
2947
100
920
1.12
0.41
4.1
3.9
18.85
8.21
mg/mmol
0.82
64
582
7
101
0.69
0.40
2.3
2.0
—
—
—
0
0
79
718
1.13
0.40
1.7
1.6
2.03
1.37
mmol/l
1.07
70
592
298
3035
0.85
0.39
53.8
17.6
222.71
245.60
e9/l
5.29
293
2956
298
3034
0.85
0.38
54.3
17.6
37.35
40.72
%
15.61
278
2817
5
37
1.36
0.37
1.4
1.2
—
1.25
—
0
12
18
222
0.80
0.36
1.5
2.1
—
—
—
0
0
270
2635
1.12
0.34
5.0
4.1
1.60
1.30
mmol/l
1.46
261
2407
16
197
0.80
0.32
1.4
1.9
—
—
—
0
0
52
470
1.13
0.30
1.2
1.3
1.19
13.47
u/ml
3.50
19
183
275
2801
0.90
0.27
5.6
5.1
2.47
2.72
mmol/l
4.90
267
2577
53
485
1.11
0.25
1.2
1.3
16.45
38.97
iu/ml
2.55
17
153
0
11
0.00
0.21
0.0
1.1
—
8.92
—
0
11
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
302.29
—
0
7
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
2.2
—
—
—
0
0
6
51
1.18
0.19
1.2
1.5
—
—
—
0
0
37
338
1.11
0.19
1.4
1.8
1.51
1.53
%
0.06
30
302
266
2698
0.93
0.17
5.4
4.6
6.11
6.01
mmol/l
0.72
251
2447
83
870
0.94
0.17
3.6
3.5
23.15
24.37
%
0.28
41
380
112
1083
1.05
0.14
4.4
3.7
6.66
1.88
ug/l
0.47
104
964
58
604
0.95
0.10
2.4
2.5
0.70
0.74
ug/l
0.15
36
387
7
68
1.03
0.08
1.1
1.2
—
2.90
—
0
6
7
80
0.87
0.07
1.1
1.2
—
9.81
—
0
12
260
2584
1.03
0.05
6.2
6.0
39.01
40.33
mmol/mol
2.00
248
2407
55
564
0.97
0.04
1.2
1.2
0.98
1.69
u/ml
—
9
155
16
167
0.96
0.01
1.2
1.3
30.65
113.31
iu/ml
—
6
67
32
313
1.02
0.01
1.6
1.4
—
—
—
0
0
43
423
1.02
0.01
1.6
1.4
—
—
—
0
0
273
2723
1.01
0.01
5.1
4.5
1.31
1.45
mmol/l
6.48
265
2504
10
101
0.99
0.00
1.9
2.6
—
—
—
0
0
274
2743
0.99
0.00
5.3
4.5
4.31
4.60
mmol/l
4.98
269
2531
5
56
0.89
0.00
1.2
1.4
—
—
—
0
0
8
80
1.00
0.00
2.0
1.8
—
—
—
0
0
5
56
0.89
0.00
1.0
1.4
—
—
—
0
0
7
75
0.93
-0.00
1.1
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
1416.86
—
0
7
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.9
—
—
—
0
0
6
69
0.87
-0.00
1.0
1.2
—
42.09
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
59
1.02
-0.00
1.2
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.9
—
—
—
0
0
7
73
0.96
-0.00
1.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
7.50
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_CML_WIDE – Chronic myeloid leukaemia, including Hilmo
GWS hits: 1
This endpoint is excluded (different definition than used in FinnGen).